Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02649972 · ClinicalTrials.gov registry record · Phase 2
Single-agent Cobimetinib for Adults With Histiocytic Disorders
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT02649972: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02649972 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02649972, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to find out what effects, good or bad, Cobimetinib has in patients with histiocytosis. Cobimetinib is an investigational oral medication that blocks MEK1.
Interventions
- DRUG Cobimetinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2016-01 |
| Est. Completion | 2022-12-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02649972
The ClinicalTrials.gov registry entry for NCT02649972 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cobimetinib is the first listed.
NCT02649972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02649972 about?
NCT02649972 is a clinical study titled "Single-agent Cobimetinib for Adults With Histiocytic Disorders". The purpose of this study is to find out what effects, good or bad, Cobimetinib has in patients with histiocytosis. Cobimetinib is an investigational oral medication that blocks MEK1.
What is the current status of trial NCT02649972?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2016-01. Estimated completion is 2022-12-16.
What interventions are being tested in trial NCT02649972?
The interventions under investigation include: Cobimetinib (DRUG).
Who is sponsoring clinical trial NCT02649972?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.